Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
<p><strong>Background:</strong> A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, C...
Main Authors: | Scheuerlein, P, Pietsch, L, Camacho-Ordonez, N, Reiser, V, Patel, S, Burns, S, Warnatz, K, Grimbacher, B |
---|---|
Format: | Journal article |
Published: |
Frontiers Media
2018
|
Similar Items
-
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01) -
Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections
by: Carlo Perricone, et al.
Published: (2021-01-01) -
Successful Use of Intravenous Immunoglobulins in an Obinutuzumab-related Acute Thrombocytopenia
by: Tobias R. Haage, et al.
Published: (2022-08-01) -
Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases
by: Paul Imbach
Published: (2012-05-01) -
Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine
by: Tsvetelina Velikova, et al.
Published: (2023-03-01)